METHOD FOR PREDICTING PROGNOSIS AND RISK OF DEVELOPING HEPATOCELLULAR CARCINOMA IN LIVER CIRRHOSIS PATIENT

摘要

The present invention provides a method and a kit for accurately predicting the prognosis (mortality rate) and risk of developing hepatocellular carcinoma in liver cirrhosis patients. The present invention provides: a method by which an "index for evaluating the risk of developing hepatocellular carcinoma," which is used for predicting the prognosis and risk of developing hepatocellular carcinoma in liver cirrhosis patients, is calculated as the ratio of CSF1R that contains WFA/VVA-binding sugars relative to the total CSF1R content of bodily fluid (blood serum) (WFA⁺–CSF1R%); and a method by which a "prognosis evaluation index" is calculated as the amount of CSF1R that contains WFA/VVA-binding sugars (WFA⁺–CSF1R ng/mL). Furthermore, an optimal cutoff value was determined for each of the indices, and it was proven that: the risk of developing hepatocellular carcinoma was significantly high when the "index for evaluating the risk of developing hepatocellular carcinoma" in a subject was equal to or greater than the optimal cutoff value; and the prognosis was significantly poor when the "prognosis evaluation index" was equal to or greater than the optimal cutoff value. In addition, anti-CSF1R antibodies (CSR-1–30), which are exceptional for detecting CSF1Rs such as CSF1Rs that contain WFA/VVA-binding sugars in a bodily fluid sample, were provided. It was discovered that srWFA and VVA lectins other than WFA lectins can be used, and it was additionally proven that measuring the amount of CSF1R that binds to a CSF1R-specific lectin is preferable to measuring the total amount of CSF1R. It was also possible to provide, inter alia, a kit for measuring the "prognosis evaluation index" and/or "index for evaluating the risk of developing hepatocellular carcinoma" in a liver cirrhosis patient, the kit including these anti-CSF1R antibodies and lectins as constituent elements.